The People Shaping Nicotine's Next Decade (and Where to Find Them)

The future of nicotine will not be shaped by a single group.

It will not be decided by scientists alone, despite the importance of evidence. It will not be determined solely by regulators, even though policy defines the operating environment. And it will not be driven by industry in isolation, regardless of its role in developing products people actually use.

Real change happens at the intersection.

The most significant public health advances emerge when different perspectives meet. When clinicians engage with behavioural scientists. When policymakers listen to economists. When innovators hear directly from users and regulators alike.

Right now, those conversations are too rare.

The World Nicotine Congress was created to change that dynamic.

In Brussels this March, WNC will convene a deliberately broad group of participants because the complexity of smoking and harm reduction demands it.

Attendees include Derek Yach, former WHO Executive Director and one of the architects of global tobacco control. Douglas Ming Deng, Professor at Yunnan University, offering insight from one of the world’s largest tobacco-producing regions. Eve Wang, Executive Director at Smoore Technology, representing device innovation at scale. Chris Junker, Group Head of Life Sciences at BAT. Economist Sinclair Davidson. Nermeen Varawalla, Chief Medical Officer at Scancell, bringing pharmaceutical and clinical trial expertise.

Scientists. Executives. Investors. Clinicians. Policy specialists. From China, Australia, Europe and the Americas.

This is a conference designed for exchanging ideas, and discussions that rarely happen.

Every session will be captured digitally to extend reach, but the real value lies in being present when ideas collide and assumptions are challenged.

If you are working on the future of nicotine in any capacity, these are the people shaping the next decade and this is where to find them.